Pasithea Therapeutics Corp (KTTA) - News Archive

: Pasithea Therapeutics Corp. (Nasdaq: KTTA) has recently made significant strides in its clinical research initiatives by activating clinical trial sites in South Korea for its Phase 1/1b study of PAS-004, aimed at tre...

Pasithea Therapeutics PAS-004 Phase 1 Trial Shows Promising Safety Profile in Advanced Cancer Treatment Pasithea Therapeutics, a nascent player in the biopharmaceutical field, has become a focal point of industry attent...

Pasithea Therapeutics has released initial results from its Phase 1 clinical trial for PAS-004, a novel therapeutic candidate aimed at treating advanced cancers, particularly those associated with neurofibromatosis type...

In the rapidly evolving world of biotech, where breakthroughs can happen overnight but financial challenges loom ominously, Pasithea Therapeutics finds itself at a pivotal crossroads. Recently, the company announced the...

Pasithea Therapeutics, a leading biotech company, has recently appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, an expert in Neurofibromatosis and Director at Mount Sinai, will be instrumental in...

Pasithea Therapeutics, a leading biopharmaceutical company focused on innovative cancer therapies, has recently achieved significant milestones in its ongoing Phase 1 clinical trial for PAS-004, a promising next-generat...

Pasithea Therapeutics (Nasdaq: KTTA) recently reached a significant milestone in their groundbreaking PAS-004 Phase 1 trial. This trial aims to evaluate the safety and efficacy of PAS-004 in patients with RAS, NF1, and...

Pasithea Therapeutics, a prominent biopharmaceutical company known for innovative drug development, has recently announced the commencement of Phase 1 trials for two of its cutting-edge products. The first trial involve...

Pasithea Therapeutics, a leading biopharmaceutical company, recently achieved a significant milestone as the U.S. Food and Drug Administration (FDA) approved their Investigational New Drug (IND) application for PAS-004,...

Highly innovative biopharmaceutical company Pasithea Therapeutics, listed on the Nasdaq as KTTA, has recently divulged promising news concerning its leading-edge research on PAS-004. In what stands as a major stepping-s...

Pasithea Therapeutics Faces Financial Challenges Amid Positive Clinical Development OutcomePasithea Therapeutics Corp, a healthcare company specializing in MEK inhibitor development, recently announced the outcome of it...

Pasithea Therapeutics Corp. Successfully Completes Tender Offer, Boosting Shareholder Confidence in Company s Growth PotentialPasithea Therapeutics Corp. recently announced the successful completion of its tender offer,...